320 related articles for article (PubMed ID: 20015073)
1. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
[TBL] [Abstract][Full Text] [Related]
2. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
3. Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528.
Asano R; Sone Y; Ikoma K; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
Protein Eng Des Sel; 2008 Oct; 21(10):597-603. PubMed ID: 18621782
[TBL] [Abstract][Full Text] [Related]
4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation pattern of humanized IgG-like bispecific antibody produced by recombinant CHO cells.
Kim WD; Tokunaga M; Ozaki H; Ishibashi T; Honda K; Kajiura H; Fujiyama K; Asano R; Kumagai I; Omasa T; Ohtake H
Appl Microbiol Biotechnol; 2010 Jan; 85(3):535-42. PubMed ID: 19652963
[TBL] [Abstract][Full Text] [Related]
6. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
[TBL] [Abstract][Full Text] [Related]
8. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
[TBL] [Abstract][Full Text] [Related]
9. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
Xie Z; Guo N; Yu M; Hu M; Shen B
J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
[TBL] [Abstract][Full Text] [Related]
11. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody.
Asano R; Kumagai T; Nagai K; Taki S; Shimomura I; Arai K; Ogata H; Okada M; Hayasaka F; Sanada H; Nakanishi T; Karvonen T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
Protein Eng Des Sel; 2013 May; 26(5):359-67. PubMed ID: 23468569
[TBL] [Abstract][Full Text] [Related]
12. Recombinant approaches to IgG-like bispecific antibodies.
Marvin JS; Zhu Z
Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
[TBL] [Abstract][Full Text] [Related]
13. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.
Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM
J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006
[TBL] [Abstract][Full Text] [Related]
16. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.
Asano R; Nakayama M; Kawaguchi H; Kubota T; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
FEBS J; 2012 Jan; 279(2):223-33. PubMed ID: 22074399
[TBL] [Abstract][Full Text] [Related]
17. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
18. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
J Gastroenterol Hepatol; 2006 Sep; 21(9):1439-47. PubMed ID: 16911690
[TBL] [Abstract][Full Text] [Related]
20. Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats.
Asano R; Hosokawa K; Taki S; Konno S; Shimomura I; Ogata H; Okada M; Arai K; Onitsuka M; Omasa T; Nakanishi T; Umetsu M; Kumagai I
Sci Rep; 2020 Mar; 10(1):4913. PubMed ID: 32188928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]